EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Investigation of tetanus seropositivity levels in adult patients with rabies risk exposure admitted to a hospital in Ankara

Pınar Gürkaynak, Şerife A Demircan, Necla Tülek, Sami Kınıklı, Fatma Ş Erdinç, Günay Tuncer

The Journal of Infection in Developing Countries · 2025-10-31 · 19 (10) · 1535-1541

DOI: 10.3855/jidc.21357 ↗
AbstractBibliografische Angaben

Abstract

Introduction: This study aimed to assess tetanus seropositivity levels among adult patients admitted to a tertiary care hospital following rabies risk exposure, and to explore potential factors influencing their immunological status. Methodology: This cross-sectional descriptive epidemiological study included 182 adult individuals (68 females and 114 males) who presented to the hospital following rabies risk exposure. The demographic data was collected during a face-to-face interview, and the tetanus antibody concentrations were assessed using a micro-enzyme-linked immunosorbent assay (ELISA) kit. Serum antibody levels of ≥ 0.1 IU/mL were defined as “seropositive”, while values below this threshold were considered “seronegative”. Results: Seropositivity was identified in 81.9% of the patients. There was a significant decline in antibody levels with age (p < 0.001). The Spearman correlation analysis showed a moderately significant negative correlation between age and antibody titers (r = – 0.404, p < 0.001). In addition, there were significantly higher tetanus antibody levels in patients from urban areas, those vaccinated during pregnancy, and those vaccinated within the past 10 years (p = 0.025, 0.036, and 0.013, respectively). Conclusions: Overall, the results highlight a reduction in tetanus antibody levels with age, emphasizing the importance of receiving a booster dose every 10 years. In addition, rabies risk exposure, particularly in older adults, presents a valuable opportunity to administer tetanus vaccination.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →